Intas and Dr. Reddy's competing with private equity firms to acquire US-based Athenex
$200–250 million (1,580-1,980 crore) proposal to buy Athenex is being discussed by India’s Intas Pharmaceuticals and Dr. Reddy’s Laboratories since the US-based biotechnology company seems to favour a controlling interest.
FDA seizes illegally stockpiled IVD kits worth Rs. 12.4 lakh in Thane
In-vitro diagnostic kits that were being marketed illegally in Thane district have been seized by Maharashtra’s Food and Drug Administration (FDA). During a raid at a facility in the Shilphata area, stock valued at Rs 12.40 lakh was taken.
Ivermectin cream from Zydus receives USFDA approval
Zydus Lifesciences Ltd announced that it has received final permission from the US Food and Drug Administration to launch its generic version of Ivermectin cream, which is used to treat inflammatory rosacea lesions.
USFDA grants final approval to Zydus for their type 2 diabetes medication
United States Food and Drug Administration has given final approval to Zydus Lifesciences Limited to market Empagliflozin tablets USP 10 mg and 25 mg.
Alembic Pharma announces 65.88cr netloss for the first quarter
In comparison to a profit of Rs 165 crore in the equivalent quarter of FY 2021–22, Vadodara–based Alembic Pharmaceuticals reported net losses of Rs 65.88 crore for the first quarter of financial year 2022–23.
As per CEO of Novo Nordisk, drug supply delays related to obesity not rare
After Wegovy was introduced in the United States last year, Novo Nordisk was unable to keep up with demand, and the company’s supply problems were made worse when a contract manufacturer had to halt production due to production problems.
Breast cancer drug Lynparza from AstraZeneca and MSD received EC approval
European Commission (EC) has given the go-ahead for AstraZeneca (AZ) and MSD’s Lynparza (olaparib) for the treatment of patients with germline BRCA-mutated HER2-negative high-risk early breast cancer.
